BioMarin Pharmaceutical Inc. (BMRN)
Last Price$70.5(2.1%)
Market Cap$13.4B
BMRN Rating
BMRN Quality rating performance
BMRN Intrinsic Value
Key Highlights:
As of Mar 11, 2025 BMRN Relative Value is $46.8, which is overvalued by 33.5%, compared to current share price of $70.5.
As of Mar 11, 2025 BMRN DCF Value is N/A, which is undervalued by N/A, compared to current share price of $70.5.
BMRN Share Price History
1W (0.0%)
1M 10.9%
6M (16.9%)
YTD (28.1%)
1Y (18.0%)
3Y (7.2%)
5Y (18.9%)
10Y (38.4%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
BMRN Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$13.4B
$12.9B
$2,850.5M
$475.4M
Shares Outstanding
191M
Employees
200K
Growth (CAGR)
10.8%
N/A
10.0%
48.86%
Profitability
78.6%
16.2%
15.0%
20.1%
16.7%
111.4%
Intrinsic Value
$46.9 (33.5% overvalued)
N/A
$46.9
$107.8
40.2%
Return on Capital
Financial Health
$1,137.7M
($535.0M)
(1.1x)
37.3x
10.7%
Dividends
Earnings
Aug 04, 2025
BEAT by 2.5%
BEAT by 41.3%
(1.1%)
9 Beat & 1 Miss
BMRN Stock Financials
BMRN Income Statement Metrics
Annual
Quarterly
LTM
BMRN Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$572.8M +259.7% YoY
Capital Expenditure (CAPEX)
($85.4M) -9.5% YoY
Free Cash Flow (FCF)
$475.4M +820.5% YoY
BMRN Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$2,853.9M 18.0% YoY
Cost of revenue
$580.2M 0.5% YoY
Pre-tax income
$541.8M 187.3% YoY
19.0% margin
BMRN Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$6,988.9M
Current assets ($3,232.4M, 46.3% of total)
$1,137.7M (16.3%)
$660.5M (9.5%)
Other current assets
$1,434.2M (20.5%)
Non-current assets ($3,756.5M, 53.7% of total)
$521.2M (7.5%)
$1,043.0M (14.9%)
$255.3M (3.7%)
Other non-current assets
$1,937.0M (27.7%)
Financial position
($535.0M)
Cash & Short-term
Investments
Total Debt
BMRN Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
BMRN Earnings Surprises
Crunching data... Almost there!
BMRN Dividends
BMRN Dividend Yield
Crunching data... Almost there!
BMRN Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with BMRN
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$14.2B | 5.6 | $42.2 38.1% overvalued | 12.0% | $4,241.2M | $235.2M | 14.8% | 5.5% | 92.3% | (12.7%) | 1.3% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is BioMarin Pharmaceutical Inc. (BMRN) stock rating?
As of today, BioMarin Pharmaceutical Inc. has a stock rating of 7 (out of 10), which is considered Good.
is BioMarin Pharmaceutical Inc. (BMRN) a good stock to buy?
As of today, BioMarin Pharmaceutical Inc. has a Good stock rating, which is 33.5% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.